Following the announcement of a £14m investment in its South Wales facility, Penn Pharma, a UK provider of pharmaceutical development and manufacturing services, has appointed Jerome Detreille as senior director of new business development.
The firm says Detreille’s role will be integral to the success of the new facility, which is due to open in January 2013.
He joins Penn Pharma from Catalent Pharma Solutions where he headed up a European sales and business development team. He has 13 years’ experience in selling services for conventional and highly potent drugs covering all dosage forms, from oral solid dose to sterile injectables.
Detreille said: ‘The expansion of our high containment operations will give us competitive advantage in the provision of highly potent development and contract manufacturing. I am looking forward to using my experience in negotiating large and complex deals to secure contracts for our expanded unit and hence drive growth for Penn.’
The construction of the new 15,000ft2 development and commercial manufacturing unit for tablets and capsules has already commenced. The facility will enable Penn to build upon its expertise in the manufacture of highly potent drugs for the worldwide market.
